Cargando…

Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer’s disease

Alzheimer’s disease (AD) is the most common neurodegenerative disease and its diagnosis has classically been based on clinical symptoms. Recently, a biological rather than a syndromic definition of the disease has been proposed that is based on biomarkers that reflect neuropathological changes. In A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Milà-Alomà, Marta, Suárez-Calvet, Marc, Molinuevo, José Luís
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6920596/ https://www.ncbi.nlm.nih.gov/pubmed/31897088 http://dx.doi.org/10.1177/1756286419888819

Ejemplares similares

Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer’s disease
por: Grau-Rivera, Oriol, et al.
Publicado: (2021)

Reference Data for Attentional, Executive, Linguistic, and Visual Processing Tests Obtained from Cognitively Healthy Individuals with Normal Alzheimer’s Disease Cerebrospinal Fluid Biomarker Levels
por: López-Martos, David, et al.
Publicado: (2023)

Enhancing the Sensitivity of Memory Tests: Reference Data for the Free and Cued Selective Reminding Test and the Logical Memory Task from Cognitively Healthy Subjects with Normal Alzheimer’s Disease Cerebrospinal Fluid Biomarker Levels
por: Brugulat-Serrat, Anna, et al.
Publicado: (2021)

Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum
por: Benedet, Andréa L., et al.
Publicado: (2021)

Alzheimer’s Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid
por: Huynh, Rose Ann, et al.
Publicado: (2017)

C-terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer disease
por: García-Ayllón, María-Salud, et al.
Publicado: (2017)

Cerebrospinal fluid Presenilin-1 increases at asymptomatic stage in genetically determined Alzheimer’s disease
por: Sogorb-Esteve, Aitana, et al.
Publicado: (2016)

Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum
por: Milà‐Alomà, Marta, et al.
Publicado: (2020)

Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome
por: Dekker, Alain D., et al.
Publicado: (2017)

Prepandemic Alzheimer Disease Biomarkers and Anxious-Depressive Symptoms During the COVID-19 Confinement in Cognitively Unimpaired Adults
por: Akinci, Muge, et al.
Publicado: (2022)

Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease
por: Rosén, Christoffer, et al.
Publicado: (2014)

Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer’s disease
por: Shaw, Leslie M., et al.
Publicado: (2018)

Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomics
por: Tijms, Betty M, et al.
Publicado: (2020)

Cerebral amyloid‐β load is associated with neurodegeneration and gliosis: Mediation by p‐tau and interactions with risk factors early in the Alzheimer's continuum
por: Salvadó, Gemma, et al.
Publicado: (2021)

Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease
por: Babić, Mirjana, et al.
Publicado: (2014)

Cerebrospinal fluid neurogranin and YKL‐40 as biomarkers of Alzheimer's disease
por: Janelidze, Shorena, et al.
Publicado: (2015)

Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer’s Disease Diagnosis
por: Bjerke, Maria, et al.
Publicado: (2018)

Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: Their Role in Clinical Chemistry
por: Blennow, Kaj, et al.
Publicado: (2000)

Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease in South Korea
por: Park, Sun Ah, et al.
Publicado: (2017)

Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum
por: Lee, Jongmin, et al.
Publicado: (2020)

Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
por: Nilsson, Johanna, et al.
Publicado: (2021)

Cerebrospinal fluid microRNAs as potential biomarkers in Alzheimer’s disease
por: Noor Eddin, Ahmed, et al.
Publicado: (2023)

Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease?
por: Del Campo Milan, Marta, et al.
Publicado: (2015)

sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers
por: Suárez‐Calvet, Marc, et al.
Publicado: (2016)

Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: Sensitivity, Specificity and Potential for Clinical Use
por: d’Abramo, Cristina, et al.
Publicado: (2020)

Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease
por: Irwin, David J., et al.
Publicado: (2020)

Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease in the Era of Disease-Modifying Treatments
por: Paraskevas, George P., et al.
Publicado: (2021)

Blood and Cerebrospinal Fluid Biomarkers of Inflammation in Parkinson’s Disease
por: Zimmermann, Milan, et al.
Publicado: (2022)

The amyloid-β isoform pattern in cerebrospinal fluid in familial PSEN1 M139T- and L286P-associated Alzheimer's disease
por: PORTELIUS, ERIK, et al.
Publicado: (2012)

Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview
por: Delaby, Constance, et al.
Publicado: (2021)

Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer’s continuum
por: Vilor-Tejedor, Natalia, et al.
Publicado: (2021)

Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers
por: Jansen, Iris E., et al.
Publicado: (2022)

The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer’s disease
por: Mäkitalo, Signar, et al.
Publicado: (2015)

Cerebrospinal fluid biomarkers of neurovascular dysfunction in mild dementia and Alzheimer's disease
por: Sweeney, Melanie D, et al.
Publicado: (2015)

Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer’s disease
por: Alexopoulos, Panagiotis, et al.
Publicado: (2016)

Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia
por: Forlenza, Orestes V., et al.
Publicado: (2015)

Association of lysophosphatidic acids with cerebrospinal fluid biomarkers and progression to Alzheimer’s disease
por: Ahmad, Shahzad, et al.
Publicado: (2020)

Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease
por: Bader, Jakob M, et al.
Publicado: (2020)

Comparison of Cerebrospinal Fluid Amyloidogenic Nanoplaques With Core Biomarkers of Alzheimer’s Disease
por: Aksnes, Mari, et al.
Publicado: (2021)

Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Current Evidence and Future Perspectives
por: McGrowder, Donovan A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_indd6u8di0lov1v1ub9q2h8rgj